{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellular+analysis&page=30", "query": { "intervention": "Cellular analysis", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 2009, "total_pages": 201, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellular+analysis&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellular+analysis&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T19:20:59.056Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04900623", "title": "Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV-Associated Oropharyngeal Squamous Cell Carcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage", "HPV-Related Squamous Cell Carcinoma", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage", "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage" ], "interventions": [ { "name": "NavDx HPV ctDNA Testing", "type": "DEVICE" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Chemotherapy drug", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "RADIATION", "DRUG" ], "sponsor": "Jonathan Schoenfeld, MD, MPH", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 145, "start_date": "2021-07-02", "completion_date": "2032-06-01", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-11-01T19:20:59.056Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900623" }, { "nct_id": "NCT01707823", "title": "Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Adenocarcinoma of the Lung", "Recurrent Non-small Cell Lung Cancer", "Stage IA Non-small Cell Lung Cancer", "Stage IB Non-small Cell Lung Cancer", "Stage IIA Non-small Cell Lung Cancer", "Stage IIB Non-small Cell Lung Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer" ], "interventions": [ { "name": "acetylsalicylic acid", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2012-10", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2020-01-14", "last_synced_at": "2026-11-01T19:20:59.056Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01707823" }, { "nct_id": "NCT01189253", "title": "Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "trabectedin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2011-05", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2014-08-08", "last_synced_at": "2026-11-01T19:20:59.056Z", "location_count": 8, "location_summary": "Santa Monica, California • Stanford, California • Iowa City, Iowa + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01189253" }, { "nct_id": "NCT04994795", "title": "Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Non-small Cell Lung Cancer Metastatic" ], "interventions": [ { "name": "Predictive models (data collection)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Sophia Genetics SAS", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4000, "start_date": "2021-08-21", "completion_date": "2025-02", "has_results": false, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-11-01T19:20:59.056Z", "location_count": 6, "location_summary": "Iowa City, Iowa • Worcester, Massachusetts • Rochester, Minnesota + 3 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04994795" }, { "nct_id": "NCT05223816", "title": "An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "VG161", "type": "DRUG" }, { "name": "Nivolumab Injection [Opdivo]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virogin Biotech Canada Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2024-01-24", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-11-01T19:20:59.056Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05223816" }, { "nct_id": "NCT02793752", "title": "Mitochondrial Activity of Cumulus Cells From the Cumulus-oocyte Complex and Oocyte Competence", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Infertility" ], "interventions": [ { "name": "Age", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Main Line Fertility Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "42 Years", "sex": "FEMALE", "summary": "21 Years to 42 Years · Female only" }, "enrollment_count": 100, "start_date": "2016-03", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2020-08-11", "last_synced_at": "2026-11-01T19:20:59.056Z", "location_count": 1, "location_summary": "Bryn Mawr, Pennsylvania", "locations": [ { "city": "Bryn Mawr", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793752" }, { "nct_id": "NCT05836584", "title": "Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage I Gastric Cancer AJCC v8", "Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage II Gastric Cancer AJCC v8", "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Lymphadenectomy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2023-12-06", "completion_date": "2027-06-28", "has_results": false, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-11-01T19:20:59.056Z", "location_count": 133, "location_summary": "Dublin, California • Fremont, California • Fresno, California + 99 more", "locations": [ { "city": "Dublin", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05836584" }, { "nct_id": "NCT00353977", "title": "Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cytomegalovirus Infections" ], "interventions": [ { "name": "ALVAC-CMV (vCP260)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 38, "start_date": "2004-05", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2014-07-08", "last_synced_at": "2026-11-01T19:20:59.056Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00353977" }, { "nct_id": "NCT01397812", "title": "Heartsbreath Test for Heart Transplant Rejection", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Heart Transplant Rejection" ], "interventions": [ { "name": "BreathScanner 1.0", "type": "DEVICE" }, { "name": "BreathLink", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Menssana Research, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1200, "start_date": "2010-12", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2015-04-07", "last_synced_at": "2026-11-01T19:20:59.056Z", "location_count": 5, "location_summary": "Beverly Hills, California • Stanford, California • Newark, New Jersey + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Newark", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01397812" }, { "nct_id": "NCT03303950", "title": "Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "ASXL1 Gene Mutation", "EZH2 Gene Mutation", "IDH1 Gene Mutation", "IDH2 Gene Mutation", "Plasma Cell Myeloma", "Primary Myelofibrosis", "Recurrent Plasma Cell Myeloma", "Secondary Myelofibrosis", "Thrombocytopenia" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 6, "start_date": "2018-03-30", "completion_date": "2020-02-19", "has_results": true, "last_update_posted_date": "2022-05-05", "last_synced_at": "2026-11-01T19:20:59.056Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03303950" } ] }